ALTO NEUROSCIENCE, INC.

Highlights Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Real-time Estimate Cboe BZX Other stock markets 07:26:53 03/06/2024 pm IST			5-day change	1st Jan Change
12.13 ^USD	+1.42%		-1.63%	0.00%

21/05	Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer	CI
14/05	Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	23/04	CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients	03/04	MT
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder	03/04	CI
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Alto Neuroscience's Shares Surge in Market Debut	03/02	MT
Alto Neuroscience Prices Upsized Initial Public Offering	02/02	MT
Alto Neuroscience, Inc. has completed an IPO in the amount of $128.64 million.	01/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer